Renaissance Technologies (RenTech)'s PCVX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 65,211 shares of Vaxcyte, Inc. (PCVX) worth $3.01 M, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in PCVX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2022, adding 428,777 shares. Largest reduction occurred in Q3 2023, reducing 215,477 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Vaxcyte (PCVX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vaxcyte (PCVX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -15,266 | Reduce 18.97% | 65,211 | $46.14 |
| Q3 2025 | -188,600 | Reduce 70.09% | 80,477 | $36.02 |
| Q2 2025 | +72,800 | Add 37.09% | 269,077 | $32.51 |
| Q1 2025 | +142,200 | Add 262.96% | 196,277 | $37.76 |
| Q4 2024 | +54,077 | New Buy | 54,077 | $81.86 |
| Q3 2023 | -215,477 | Sold Out | 0 | $0.00 |
| Q2 2023 | -205,400 | Reduce 48.80% | 215,477 | $0.05 |
| Q1 2023 | -101,100 | Reduce 19.37% | 420,877 | $0.04 |
| Q4 2022 | +428,777 | Add 460.06% | 521,977 | $0.05 |
| Q3 2022 | +20,600 | Add 28.37% | 93,200 | $24.00 |
| Q2 2022 | +31,800 | Add 77.94% | 72,600 | $21.76 |
| Q1 2022 | +27,800 | Add 213.85% | 40,800 | $24.14 |
| Q4 2021 | +13,000 | New Buy | 13,000 | $23.77 |
Renaissance Technologies (RenTech)'s Vaxcyte Investment FAQs
Renaissance Technologies (RenTech) first purchased Vaxcyte, Inc. (PCVX) in Q4 2021, acquiring 13,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Vaxcyte, Inc. (PCVX) for 13 quarters since Q4 2021.
Renaissance Technologies (RenTech)'s largest addition to Vaxcyte, Inc. (PCVX) was in Q4 2022, adding 521,977 shares worth $25,029.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 65,211 shares of Vaxcyte, Inc. (PCVX), valued at approximately $3.01 M.
As of the Q4 2025 filing, Vaxcyte, Inc. (PCVX) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Vaxcyte, Inc. (PCVX) was 521,977 shares, as reported at the end of Q4 2022.